Let's play "Antibodies for Alzheimers!"





































It's getting beyond absurd how much money Lilly keeps pouring down the A-beta rabbit hole.

The original mAb patent was filed in 2002 and has now failed 3 trials, but hey, it's on to EXPEDITION 4?

At what point does management wake up and pull the plug?
 












It's getting beyond absurd how much money Lilly keeps pouring down the A-beta rabbit hole.

The original mAb patent was filed in 2002 and has now failed 3 trials, but hey, it's on to EXPEDITION 4?

At what point does management wake up and pull the plug?

Some very terrible, horrible horrible people say these trials are all about spoofing Wall Street analysts.

That would never happen here.

But seriously, the company basically walks in lock-step with whatever the latest mantra is (like "Antibodies for Alzheimers") -- look back at the history here- still trying to justify a colossal acquisition mistake. Dissent should be encouraged within the ranks. Do something like Google does, have a couple dozen different subsidiaries, let them run with their pet projects.

I've been studying this area for years. It's basically a matter of addressing a dozen or so different targets, and sorry, there is no single magic bullet, and there never will be.